Key Takeaways
- • Matchpoint Therapeutics closed a $150 million Series B financing round co-led by Nextech Invest and Norwest, advancing its precision covalent medicines platform.
- • New institutional investors including Invus, BB Biotech, T1D Fund, and BOLD Longevity Growth participated in the round alongside the lead investors.
- • The funding positions Matchpoint to accelerate discovery and development of targeted small-molecule therapeutics with enhanced specificity and reduced off-target effects.
Summary
Matchpoint Therapeutics, a Watertown-based biotechnology company, announced the successful close of a $150 million Series B funding round on October 7, 2026. The round was co-led by Nextech Invest and Norwest, two prominent healthcare-focused investment firms, signaling confidence in the company's precision covalent medicine approach.
The financing included participation from four new institutional investors: Invus, BB Biotech, T1D Fund, and BOLD Longevity Growth. This diverse investor syndicate reflects investor interest in Matchpoint's platform for discovering covalent therapeutics—small molecules designed to form irreversible bonds with disease-causing proteins, offering improved selectivity and durability compared to conventional approaches.
The Series B capital infusion provides Matchpoint with substantial resources to expand its drug discovery pipeline, advance clinical development programs, and strengthen its operational infrastructure. The company's focus on precision covalent medicines addresses a growing therapeutic category that has gained significant traction among biopharma investors and pharmaceutical partners seeking differentiated mechanisms of action.
The financing included participation from four new institutional investors: Invus, BB Biotech, T1D Fund, and BOLD Longevity Growth. This diverse investor syndicate reflects investor interest in Matchpoint's platform for discovering covalent therapeutics—small molecules designed to form irreversible bonds with disease-causing proteins, offering improved selectivity and durability compared to conventional approaches.
The Series B capital infusion provides Matchpoint with substantial resources to expand its drug discovery pipeline, advance clinical development programs, and strengthen its operational infrastructure. The company's focus on precision covalent medicines addresses a growing therapeutic category that has gained significant traction among biopharma investors and pharmaceutical partners seeking differentiated mechanisms of action.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.